Bristol-Myers Squibb vs Johnson & Johnson: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson and is led by Joaquin Duato.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Johnson & Johnson
- Founded
- 1886
- Headquarters
- New Brunswick, New Jersey
- Current CEO
- Joaquin Duato
- Employees
- 140,800
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Johnson & Johnson
Robert Wood Johnson
Robert Wood Johnson (1845-1910) co-founded Johnson & Johnson in 1886 and served as its first president.
James Wood Johnson
James Wood Johnson (1856-1932) co-founded J&J with his brothers in 1886. An engineer by trade, he designed the early manufacturing machinery that allowed the company to mass-produce sterile surgical dressings.
Edward Mead Johnson
Edward Mead Johnson (1852-1934) co-founded J&J in 1886, bringing crucial sales and marketing expertise to the early business.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Johnson & Johnson
- Ralph Larsen1989–2002
Former Chairman and Chief Executive Officer
Larsen's acquisitions, including Neutrogena, Cordis, DePuy, and Centocor, broadened J&J into medical devices and biologics, laying groundwork for today's MedTech segment and immunology franchise.
Source - William Weldon2002–2012
Former Chairman and Chief Executive Officer
Weldon's later years were overshadowed by a wave of consumer product recalls, including Tylenol and Motrin, tied to manufacturing-quality problems.
Source - Alex Gorsky2012–2022
Former Chairman and Chief Executive Officer
Gorsky's tenure set up the 2023 Kenvue separation completed under his successor and saw J&J's single-dose COVID-19 vaccine authorized in 2021. He also oversaw the $30 billion Actelion acquisition in 2017 and the early years of talc litigation.
Source - Joaquin Duato2022–present
Chairman and Chief Executive Officer
Under Duato, J&J's sales reached $94.193 billion in FY2025 with $26.804 billion in net earnings, and the company guides to its first $100 billion year in 2026. He also launched the DePuy Synthes separation and the 2026 talc settlement proposal.
Source
Timeline: Bristol-Myers Squibb and Johnson & Johnson side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1886Johnson & Johnson
Johnson & Johnson Founded
Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found the company in New Brunswick, New Jersey, with 14 employees, to mass-produce sterile surgical dressings after Robert was inspired by antiseptic pioneer Joseph Lister's 1885 warnings about i…
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1920Johnson & Johnson
Band-Aid Brand Adhesive Bandages Introduced
J&J introduces the first mass-produced adhesive bandage, sold under the Band-Aid brand starting in 1921; it becomes one of the most recognized consumer-health brands in the world before J&J later spins its consumer division out as Kenvue in 2023.
1943Johnson & Johnson
Robert Wood Johnson II Writes 'Our Credo'
Chairman Robert Wood Johnson II authors 'Our Credo,' a one-page statement ranking the company's responsibilities to customers, employees, communities, and shareholders in that order; it remains J&J's official governing philosophy and was later cited as the bas…
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1944Johnson & Johnson
J&J Goes Public
Johnson & Johnson lists publicly, becoming an independent, market-traded company as it expands into a diversified healthcare business under Chairman Robert Wood Johnson II.
1982Johnson & Johnson
Tylenol Cyanide Poisonings and Nationwide Recall
After seven people in the Chicago area die from cyanide-laced Extra-Strength Tylenol capsules, J&J issues a nationwide recall of 31 million bottles within a week -- far beyond what investigators said was necessary -- citing Our Credo's customer-safety priority…
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2012Johnson & Johnson
Alex Gorsky Becomes CEO
Gorsky succeeds William Weldon as CEO amid a period of manufacturing-quality recalls, and spends the next decade restoring J&J's operational reputation while expanding the pharmaceutical and MedTech businesses and developing a single-dose COVID-19 vaccine duri…
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Johnson & Johnson
Joaquin Duato Becomes CEO
Duato becomes CEO in January 2022, later adding the chairman title, and begins preparing the separation of J&J's consumer-health business from its medicine and device operations.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Johnson & Johnson
Kenvue Separation
J&J completes the spinoff of its consumer-health business (Band-Aid, Tylenol, Listerine, Neutrogena) as the standalone public company Kenvue, narrowing J&J around its higher-margin Innovative Medicine and MedTech segments.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Johnson & Johnson
FY2025 Sales of $94.193B
Johnson & Johnson reports $94.193 billion in sales and $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year.
2025Johnson & Johnson
Orthopaedics Separation Announced
In October 2025 J&J announced plans to separate its orthopaedics business as a standalone company operating as DePuy Synthes, targeting completion in 2027.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Johnson & Johnson
Proposed Talc Resolution and Raised Guidance
J&J raised 2026 sales guidance to about $101.1 billion after Q2 sales of $25.31 billion, and on July 27, 2026 proposed an estimated $5.5 billion resolution of remaining ovarian talc claims.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Johnson & Johnson
- Intra-Cellular Therapies2025$14.6B
- Shockwave Medical2024$13.1B
- Kenvue separation2023Undisclosed
- Abiomed2022$16.6B
- Actelion2017$30B
Questions about Bristol-Myers Squibb vs Johnson & Johnson
Who is the CEO of Bristol-Myers Squibb Company and Johnson & Johnson?
Bristol-Myers Squibb Company is led by Christopher Boerner and Johnson & Johnson is led by Joaquin Duato. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Johnson & Johnson?
Johnson & Johnson was founded in 1886 — 1 year before Bristol-Myers Squibb Company, which was founded in 1887. Johnson & Johnson's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bristol-Myers Squibb Company.
How many employees does Bristol-Myers Squibb Company have compared to Johnson & Johnson?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Johnson & Johnson employs approximately 140,800. Johnson & Johnson has the larger workforce at 140,800 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Johnson & Johnson headquartered?
Both Bristol-Myers Squibb Company and Johnson & Johnson are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Johnson & Johnson?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Johnson & Johnson was founded by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson.
Which company has a longer operating history — Bristol-Myers Squibb Company or Johnson & Johnson?
Johnson & Johnson has been operating for approximately 140 years, making it the more established of the two companies. Bristol-Myers Squibb Company has been in operation for around 139 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Johnson & Johnson overview